NCT03421002View on ClinicalTrials.gov

Determination of Levels of Micafungin in Neonates Suffering From Systemic Candidiasis and/or Candida Meningitis

PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

May 30, 2015

Primary Completion Date

April 10, 2018

Study Completion Date

April 10, 2018

Conditions
Candidiasis, SystemicCandida Meningitis
Interventions
DRUG

Micafungin

Participants will receive micafungin 8 mg/kg per day via intravenous infusion for approximately 1 hour.

Trial Locations (2)

00146

Site IT39001, Rome

00186

Site IT39002, Rome

All Listed Sponsors
collaborator

IRCCS, Ospedale Pediatrico Bambino Gesu

UNKNOWN

lead

Astellas Pharma Global Development, Inc.

INDUSTRY

NCT03421002 - Determination of Levels of Micafungin in Neonates Suffering From Systemic Candidiasis and/or Candida Meningitis | Biotech Hunter | Biotech Hunter